Chemokines: structure, receptors and functions. A new target for inflammation and asthma therapy?

Mediators of Inflammation

Volumn 5, Issue 6, 1996, Pages 393-416

  Van Acker, F A A ^a   Voss, H P ^a   Timmerman, H ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Airway inflammations; Asthma; Chemokines

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; GLUCOCORTICOID; INTERLEUKIN 8; RANTES;

ASTHMA; BASOPHIL; CHEMOTAXIS; CHROMOSOME 17; CHROMOSOME 4; EOSINOPHIL; HUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW;

EID: 0030477208     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/S0962935196000567     Document Type: Article

References (96)

1. Voss H-P. Long-acting ß2-adrenoceptor agonists in asthma: molecular pharmacological aspects. Thesis, Vrije Universiteit Amsterdam, 1994.
2. Barnes PJ. Anti-inflammatory therapy. Annu Rev Med 1993; 44: 229–242.
3. Virchow JC Jr, Kroegel C, Walker C, Matthys H. Cellular and immunological markers of allergic and intrinsic bronchial asthma. Lung 1994; 172: 313–334.
4. Shelhamer JH, Levine SJ, Wu T, Jacoby DB, Kaliner MA, Rennard SI. NIH conference. Airway inflammation. Ann Intern Med 1995; 123: 288–304.
5. Rang HP, Dale MM, Ritter JM, eds. The respiratory system. In: Pharmacology. New York: Churchill Livingstone, 1995; 351–366.
6. Linssen M. Animal models for the selection of anti-inflammatory compounds for the treatment of bronchial hyperreactivity in asthma. Thesis, Vrije Universiteit Amsterdam, 1990.
7. Kay AB, Corrigan CJ. Eosinophils and neutrophils. Br Med Bull 1992; 48: 51-64.
8. Barnes PJ, ed. Asthma. Vol 48. London: Churchill Livingstone, 1992.
9. Doelman CJA. Reactive oxygen species and airway hyperreactivity. Thesis, Vrije Universiteit Amsterdam, 1991.
10. Kirby JG, Hargreave FE, Gleich CJ, O’Byrne PM. Bronchoalveolar cell profiles of asthmatic and nonasthmatic subjects. Am Rev Respir Dis 1987; 136: 379–383.
11. Wardlaw AJ, Dunnete S, Gleich GJ, Collins JV, Kay AB. Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Am Rev Respir Dis 1988; 137: 62–69.
12. Ädelroth E, Rosenhall L, Johansson SÁ, Linden M, Venge P. Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage: the effects of anti-asthmatic treatment with budesonide or terbutaline. Am Rev Respir Dis 1990; 142: 91–99.
13. Jeffrey PK, Wardlaw AJ, Nelson FC, Collins JV, Kay AB. Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity. Am Rev Respir Dis 1989; 140: 1745–1753.
14. Beasley R, Roche WR, Roberts JA, Holgate ST. Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis 1989; 139: 806–817.
15. O’Byrne PM. What is asthma? An update on the mechanisms. J Invest Allergol Clin Immunol 1995; 5: 6–11.
16. Azzawi M, Bradley B, Jeffery PK, Frew AJ, Wardlaw AJ, Knowles G, Assoufi B, Collins JV, Durham S, Kay AB. Identification of activated T- lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am Rev Respir Dis 1990; 142: 1407–1413.
17. Bochner BS, Undem BJ, Lichtenstein LM. Immunological aspects of allergic asthma. Annu Rev Immunol 1994; 12: 295–335.
18. Dale HH, Laidlaw PP. The physiological action of ß-imida- zolylethylamine. J Physiol (London) 1910; 41: 318–344.
19. Schwartz L, Huff T. Biology of mast cells and basophils. In: Middleton E, Reed CE, Ellis EF, Adkinson Jr NF, Yunginger JW, Busse W, eds. Allergy Principles and Practice. St Louis: Mosby, 1993; 135–168.
20. Henocq E, Vargaftig BB. Accumulation of eosinophils in response to intracutaneous PAF-acether and allergen in man. Lancet 1986; 2: 1378–1379.
21. Gundel RH, Letts LG, Gleich GJ. Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. J Clin Invest 1991; 87: 1470–1473.
22. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines: CXC and CC chemokines. Adv Immunol 1994; 55: 97–179.
23. Stricter RM, Koch AE, Antony VB, Fick Jr RB, Stradiford TJ, Kunkel SL. The immunopathology of chemotactic cytokines: the role of interleukin–8 and monocyte chemoattractant protein-1. J Lab Clin Med 1994; 123: 183–197.
24. Horuk R. Molecular properties of the chemokine receptor family. TIPS 1994; 15: 159–165.
25. Pruzanski W, Vadas P, eds. Novel Molecular Approaches to Antiinflammatory Theory. Vol. 46. Basel: Birkhäuser Verlag, 1995; 1–22.
26. Boyden Jr SE. The chemotactic effects of mixtures of antibody and antigen on polymorphonuclear leukocytes. J Exp Med 1962; 115: 453–466.
27. Murphy PM. The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol 1994; 12: 593–633.
28. Oppenheim JJ, Zachariae COC, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene ‘intercrine’ cytokine family. Annu Rev Immunol 1991; 9: 617–648.
29. Luster AS, Unkeless JC, Ravetch JV Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 1985; 315: 672–676.
30. Yoshimura TK, Matsushima K, Tanaka S, Robinson EA, Appella E, Oppenheim JJ, Leonard EJ. Purification of a human monocyte-derived neutrophil chemotactic factor that shares sequence homology with other host defense cytokines. Proc Natl Acad Set USA 1987; 84: 9233–9237.
31. Yoshimura TK, Matsushima K, Oppenheim JJ, Leonard EJ. Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization and separation from interleukin 1 (IL 1). J Immunol 1987; 139: 788–793.
32. Meurer R, Riper GV, Feeney W, Cunningham P, Hora Jr D, Springer MS, MacIntyre DE, Rosen H. Formation of eosinophilic and monocytic intradermal inflammatory sites in the dog by injection of human RANTES but not human monocyte chemoattractant protein 1, human macrophage inflammatory protein la, of human interleukin 8. J Exp Med 1993; 178: 1913–1921.
33. Keiner GS, Kennedy J, Bacon KB, Kleyensteuber S, Largaespada DA, Jenkins NA, Copeland NG, Bazan JF, Moore KW, Schall TJ, Zlotnik A. Lymphotactin: a cytokine that represents a new class of chemokine. Science 1994; 266: 1395–1399.
34. Keiner G, Zlotnik A. Cytokine production profile of early thymocytes and the characterization of a new class of chemokine. J Leuk Biol 1995; 57: 778–-781.
35. Kennedy J, Keiner GS, Kleyensteuber S, Schall TJ, Weiss MC, Yssel H, Schneider PV, Cocks BG, Bacon KB, Zlotnik A. Molecular cloning and functional characterization of human lymphotactin. J Immunol 1995; 155: 203–209.
36. Clark-Lewis I, Kim K-S, Rajarathnam K, Gong J-H, Dewald B, Moser B, Baggiolini M, Sykes BD. Structure-activity relationships of chemokines. J Leuk Biol 1995; 57: 703–711.
37. Färber JM. HuMIG: a new member of the chemokine family of cytokines. Biochem Biophys Res Comm 1993; 192: 223–230.
38. Proost P, De Wolf-Peeters C, Conings R, Opdenakker G, Billiau A, Van Damme J. Identification of a novel granulocyte chemotactic protein (GCP-1) from human tumor cells: in vitro and in vivo comparison with natural forms of GROa, IP–10, and IL–8. J Immunol 1993; 150: 1000–1010.
39. Schall TJ, Bacon KB. Chemokines, leukocyte trafficking, and inflammation. Curr Opin Immunol 1994; 6: 865–873.
40. Chaudhuri A, Polyakova J, Zbrzezna V, Williams K, Gulati S, Pogo AO. Cloning of glycoprotein D cDNA which encodes the major subunit of the Duffy blood group system and the receptor for the plasmodium vivax malaria parasite. Proc Natl Acad Set USA 1993; 90: 10793–10797.
41. Horuk R, Colby TJ, Darbonne WC, Schall TJ, Neote K. The human erythrocyte inflammatory peptide (chemokine) receptor. Biochemical characterization, solubilization, and development of a binding assay for the soluble receptor. Biochemistry 1993; 32: 5733–5738.
42. Neote K, DiGregorio D, Mak JY, Horuk R, Schall T. Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. Cell 1993; 72: 415–425.
43. Schall TJ, Stein B, Gorgone G, Bacon KB. Cytomegalovirus encodes a functional receptor for C-C chemokines. In: McFadden G, ed. Virocep- tors, Virokines and Related Immune Modulators Encoded by DNA Viruses. RG Landes; Chapter 12.
44. Ahuja SK, Murphy PM. Molecular piracy of mammalian interleukin-8 receptor type B by herpesvirus saimiri. J Biol Chem 1993; 268: 20691–20694.
45. Moser B, Schumacher C, von Tscharner V, Clark-Lewis I, Baggiolini M. Neutrophil-activating peptide 2 and gro / melanoma growth-stimulatory activity interact with neutrophil-activating peptide 1/interleukin-8 receptors on human neutrophils. J Biol Chem 1991; 266: 10666–10671.
46. Schumacher C, Clark-Lewis I, Baggiolini M, Moser B. High- and low- affinity binding of GROa and neutrophil-activating peptide 2 to interleukin-8 receptors on human neutrophils. Proc Natl Acad Set USA 1992; 89: 10542–10546.
47. Baggiolini M, Loetscher P, Moser B. Interleukin-8 and the chemokine family. Int J Immunopharm 1995; 17: 103–108.
48. Kelvin DJ, Michiel DF, Johnston JA, Lloyd AR, Sprenger H, Oppenheim JJ, Wang J-M. Chemokines and serpentines: the molecular biology of chemokine receptors. J Leuk Biol 1993; 54: 604–612.
49. Samanta AK, Oppenheim JJ, Matsushima T. Interleukin 8 (monocyte- derived neutrophil chemotactic factor) dynamically regulates its own receptor expression on human neutrophils. J Biol Chem 1990; 265: 183.
50. Besemer J, Hujber A, Kuhn B. Specific binding, internalization, and degradation of human neutrophil activating factor by human polymorphonuclear leukocytes. J Biol Chem 1989; 264: 17409
51. Grob PM, David E, Warren TC, DeLeon RP, Farina PR, Homon CA. Characterization of a receptor for human monocyte-derived neutrophil chemotactic factor/interleukin–8. J Biol Chem 1990; 265: 8311.
52. Chuntharapai A, Kim KJ. Regulation of the expression of IL-8 receptor A/B by IL-8: possible functions of each receptor. J Immunol 1995; 155:2587–2594.
53. Chuntharapai A, Lee J, Hebert C, Kim KJ. Monoclonal antibodies detect different distribution patterns of IL-8 receptor A and IL-8 receptor B on human peripheral blood leukocytes. J Immunol 1994; 153: 5682.
54. Lee J, Horuk R, Rice GC, Bennett GL, Camerato T, Wood WI. Characterization of two high affinity human interleukin-8 receptors. J Biol Chem 1992; 267: 16283.
55. Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B. Both interleukin-8 receptors independently mediate chemotaxis. Jurkat cells transfected with IL-8R1 of IL-8R2 migrate in response to IL-8, GROa and NAP-2. FEBS Lett 1994; 341: 187.
56. Hébert CA, Chuntharapai A, Smith M, Colby T, Kim J, Horuk R. Partial functional mapping of the human interleukin-8 type A receptor. J Biol Chem 1993; 268: 18549–18553.
57. Clark-Lewis I, Schumacher C, Baggiolini M, Moser B. Structure-activity relationships of interleukin-8 determined using chemically synthesized analogs. Critical role for NH2 terminal residues and evidence for uncoupling of neutrophil chemotaxis, exocytosis, and receptor binding activities. J Biol Chem 1991; 266: 23128–23134.
58. Hébert CA, Vitangcol RV, Baker JB. Scanning mutagenesis of interleukin-8 identifies a cluster of residues required for receptor binding. J Biol Chem 1991; 266: 18989–18994.
59. Probst WC, Snyder LA, Schuster DI, Brosius J, Sealfon SC. Sequence alignment of the G-protein coupled receptor family. DNA Cell Biol 1992; 11: 1-20.
60. Gao J-L, Kuhns DB, Tiffany HL, McDermott D, Li X, Francke U, Murphy PM. Structure and functional expression of the human macrophage inflammatory protein la/RANTES receptor. J Exp Med 1993; 177: 1421–1427.
61. Wang J-M, Sherry B, Fivash MJ, Kelvin DJ, Oppenheim JJ. Human recombinant macrophage inflammatory protein-la and -ß and monocyte chemotactic and activating factor utilize common and unique receptors on human monocytes. J Immunol 1993; 150: 1–8.
62. Wang J-M, McVicar DW, Oppenheim JJ, Kelvin DJ. Identification of RANTES receptor on human monocytic cells: competition for binding and desensitization by homologous chemotactic cytokines. J Exp Med 1993; 177: 699–705.
63. Charo IF, Myers SJ, Herman A, Franci C, Connolly AJ, Coughlin SR. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc Natl Acad Sei USA 1994; 91: 2752–2756.
64. Combadiere C, Ahuja SK, Murphy PM. Cloning and functional expression of a human eosinophil CC chemokine receptor. J Biol Chem 1995; 270: 16491–16494.
65. Combadiere C, Ahuja SK, Murphy PM. Cloning, chromosomal localization, and RNA expression of a human beta chemokine receptor-like gene. DNA Cell Biol 1995; 14: 673–680.
66. Jose PJ, Griffiths-Johnson DA, Collins PD, Walsh DT, Moqbel R, Totty NF, Truong O, Hsuan JJ, Williams TJ. Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model for allergic airways inflammation. J Exp Med 1994; 179: 881–887.
67. Raport CJ, Schweickart VL, Chantry D, Eddy Jr RL, Shows TB, Godiska R, Gray PW. New members of the chemokines receptor gene family. J Leuk Biol 1996; 59: 18–23.
68. Wells TNC, Power CA, Lusti-Narasimhan M, Hoogewerf AJ, Cooke RM, Chung C, Peitsch MC, Proudfoot AEI. Selectivity and antagonism of chemokine receptors. J Leuk Biol 1996; 59: 53–60.
69. Neote K, Darbonne W, Ogez J, Horuk R, Schall TJ. Identification of a promiscuous inflammatory peptide receptor on the surface of red blood cells. J Biol Chem 1993; 268: 12247–12249.
70. Darbonne WC, Rice GC, Möhler MA, Apple T, Hébert CA, Valente AJ, Baker JB. Red blood cells are a sink for interleukin 8, a leukocyte chemotaxin. Clin Invest 1991; 88: 1362–1369.
71. Holmes WE, Lee J, Kuang W-J, Rice G, Wood WI. Structure and functional expression of a human interleukin-8 receptor. Science 1991; 253:1278–1280.
72. 27 introduces CC chemokine activity into interleukin-8. J Biol Chem 1995; 270: 2716-–2721.
73. Moser B, Dewald B, Barella L, Schumacher C, Baggiolini M. Interleukin- 8 antagonists generated by N-terminal modification. J Biol Chem 1993; 268: 7125.
74. Clark-Lewis I, Dewald B, Greiser T, Moser B, Baggiolini M. Platelet factor 4 binds to interleukin–8 receptors and activates neutrophils when its N terminus is modified with Glu–Leu–Arg. Proc Natl Acad Set USA 1993; 90: 3574–3577.
75. Gong J-H, Clark-Lewis I. Antagonists of monocyte chemoattractant protein-1 identified by modification of functionally critical NH2– terminal residues. J Exp Med 1995; 181: 631–640.
76. Beall CJ, Mahajan S, Kolattukudy PE. Conversion of monocyte chemoattractant protein-1 into a neutrophil attractant by substitution of two amino acids. J Biol Chem 1992; 267: 3455–3459.
77. Lasky LA. Combinatorial mediators of inflammation? Curr Biol 1993; 3: 366-368.
78. Baggiolini M, Dahinden CA. CC chemokines in allergic inflammation. Immunology Today 1994; 15: 127–133.
79. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301–314.
80. Butcher EC Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991; 67: 1033–1036.
81. Laskey LA. Selectins: interpreters of cell-specific carbohydrate information during inflammation. Science 1992; 258: 964–969.
82. Shimizu Y, Newman W, Tanaka Y. S Lymphocyte interactions with endothelial cells. Lmmunol Today 1992; 13: 106–112.
83. Roitt I, Brostoff J, Male D. Immunology. 3rd edition. St Louis: Mosby, 1993.
84. Devreotes PN, Zigmond SH. Chemotaxis in eukaryotic cells: a focus on leukocytes and Dictyostelium. Annu Rev Cell Biol 1988; 4: 649–686.
85. Tanaka Y, Adams DH, Huscher S, Hirano H, Siebenlist U, Shaw S. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP–lß. Nature 1993; 361: 79–82.
86. Ebisawa M, Yamada T, Bickel C, Klunk D, Schleimer RP. Eosinophil transendothelial migration induced by cytokines. III. Effect of the chemokine RANTES. J Immunol 1994; 153: 2153–2160.
87. Dahinden CA, Geiser T, Brunner T, Tscharner W, Caput D, Ferrara P, Minty A, Baggiolini M. Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating chemokine. J Exp Med 1994; 179: 751–756.
88. Ben-Baruch A, Xu L, Young PR, Bengali K, Oppenheim JJ, Wang JM. Monocyte chemotactic protein-3 (MCP-3) interacts with multiple leukocyte receptors. J Biol Chem 1995; 270: 22123–22128.
89. Proost P, Wuyts A, Damme JV. Human monocyte chemotactic proteins- 2 and -3: structural and functional comparison with MCP–1. J Leuk Biol 1996; 59: 67–74.
90. Rothenberg ME, Luster AD, Leder P. Murine eotaxin: an eosinophil chemoattractant inducible in endothelial cells and in interleukin 4- induced tumor suppression. Proc Natl Acad Sei USA 1995; 92: 8960–8964.
91. Griffiths-Johnson DA, Collins PD, Rossi AG, Jose PJ, Williams TJ. The chemokine eotaxin, activates guinea-pig eosinophils in vitro and causes their accumulation into the lung in vivo. Biochem Biophys Res Comm 1993; 197: 1167–1172.
92. Rothenberg ME, Luster AD, Lilly CM, Drazen JM, Leder P. Constitutive and allergen-induced expression of eotaxin mRNA in the guinea piglung. J Exp Med 1995; 181: 1211–1216.
93. In: SanverTecho, December 1995.
94. Ponath PD, Qin S, Ringler DJ, Clark-Lewis I, Wang J, Kassam N, Smith H, Shi X, Gonzalo J-A, Newman W, Gutierrez-Ramos J-C, Mackay CR. Cloning of the human eosinophil chemoattractant, eotaxin. J Clin Invest 1996; 97: 604–612.
95. Stellato C, Beck LA, Gorgone GA, Proud D, Schall TJ, Ono SJ, Lichtenstein LM, Schleimer RP. Expression of the chemokine RANTES by a human bronchial epithelial cell line. Modulation by cytokines and glucocorticoids. J Immunol 1995; 155: 410–418.
96. Rang HP, Dale MM, Ritter JM. Anti-inflammatory and immunosuppressant drugs. In: Pharmacology. New York: Churchill Livingstone, 1995.